Literature DB >> 12185296

Guidelines for the treatment of recurrent and metastatic cervical cancer.

Michael Friedlander1, Michelle Grogan.   

Abstract

Although there have been important advances in the management of women with cervical cancer, the optimal treatment for patients with locally recurrent and metastatic disease is still problematic, and there are relatively few randomized trials to guide treatment decisions. This paper reviews the approach to management of patients who relapse after primary treatment for cervical cancer. Patients who are still potentially curable with radical treatment are identified, and the various treatment strategies are discussed. However, most women are treated with palliative intent, and the literature on palliative management is reviewed together with the levels of evidence.

Entities:  

Mesh:

Year:  2002        PMID: 12185296

Source DB:  PubMed          Journal:  Oncologist        ISSN: 1083-7159


  55 in total

1.  Extracellular matrix metalloproteinase inducer (CD147/BSG/EMMPRIN)-induced radioresistance in cervical cancer by regulating the percentage of the cells in the G2/m phase of the cell cycle and the repair of DNA Double-strand Breaks (DSBs).

Authors:  Xingzhu Ju; Shanhui Liang; Jun Zhu; Guihao Ke; Hao Wen; Xiaohua Wu
Journal:  Am J Transl Res       Date:  2016-06-15       Impact factor: 4.060

Review 2.  The current status of immunotherapy for cervical cancer.

Authors:  Cecilia Orbegoso; Krithika Murali; Susana Banerjee
Journal:  Rep Pract Oncol Radiother       Date:  2018-05-18

3.  Staging, recurrence and follow-up of uterine cervical cancer using MRI: Updated Guidelines of the European Society of Urogenital Radiology after revised FIGO staging 2018.

Authors:  Lucia Manganaro; Yulia Lakhman; Nishat Bharwani; Benedetta Gui; Silvia Gigli; Valeria Vinci; Stefania Rizzo; Aki Kido; Teresa Margarida Cunha; Evis Sala; Andrea Rockall; Rosemarie Forstner; Stephanie Nougaret
Journal:  Eur Radiol       Date:  2021-04-14       Impact factor: 5.315

4.  Myricetin and methyl eugenol combination enhances the anticancer activity, cell cycle arrest and apoptosis induction of cis-platin against HeLa cervical cancer cell lines.

Authors:  Jin-Ling Yi; Song Shi; Yan-Li Shen; Ling Wang; Hai-Yan Chen; Jun Zhu; Yan Ding
Journal:  Int J Clin Exp Pathol       Date:  2015-02-01

5.  Nonsurgical management of cervical cancer: locally advanced, recurrent, and metastatic disease, survivorship, and beyond.

Authors:  Helen J Mackay; Lari Wenzel; Linda Mileshkin
Journal:  Am Soc Clin Oncol Educ Book       Date:  2015

6.  Squamous cell carcinoma of cervix origin with rare metastasis to the colon.

Authors:  Andrew Lelchuk; Nicholas Morin; Kevin Bain
Journal:  AME Case Rep       Date:  2018-05-15

7.  Prediction of disease progression following concurrent chemoradiotherapy for uterine cervical cancer: value of post-treatment diffusion-weighted imaging.

Authors:  Jung Jae Park; Chan Kyo Kim; Byung Kwan Park
Journal:  Eur Radiol       Date:  2015-12-18       Impact factor: 5.315

8.  Treatment options in recurrent cervical cancer (Review).

Authors:  Angiolo Gadducci; Roberta Tana; Stefania Cosio; Luca Cionini
Journal:  Oncol Lett       Date:  2010-01-01       Impact factor: 2.967

9.  Comparison of 18F-FDG PET/MRI and MRI alone for whole-body staging and potential impact on therapeutic management of women with suspected recurrent pelvic cancer: a follow-up study.

Authors:  Lino M Sawicki; Julian Kirchner; Johannes Grueneisen; Verena Ruhlmann; Bahriye Aktas; Benedikt M Schaarschmidt; Michael Forsting; Ken Herrmann; Gerald Antoch; Lale Umutlu
Journal:  Eur J Nucl Med Mol Imaging       Date:  2017-11-21       Impact factor: 9.236

10.  Femur metastasis in carcinoma of the uterine cervix: a rare entity.

Authors:  Giacomo Corrado; Salvatore Santaguida; Gianfranco Zannoni; Giovanni Scambia; Gabriella Ferrandina
Journal:  Arch Gynecol Obstet       Date:  2009-12-02       Impact factor: 2.344

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.